Fig. 3

Plasma exposure profile of ML375 after (a) 20 mg/kg (intraperitoneal; i.p.) or (b) 30 mg/kg (per os; p.o.) dose (n = 3). Brain exposure was also measured at 24 h after IP injection. (c) Superposition of oral exposure profiles provides a prediction of plasma exposure of ML375 for an operant chamber test session after three doses of ML375, each at 30 mg/kg (p.o.)